We evaluated CHMP5-depleted T-ALL response to the targeted therapy combination of γ-secretase inhibitors plus dexamethasone (“GSI+Dex”), in trial for NOTCH1-dependent T-ALL60–62. Here, NOTCH1 is linked to acute lymphoblastic leukemia.